Abeid Athman (Omar).
@bin_abeid
Clinical Oncologist at @KUTRRH.
Fellow at European School of Oncology @ESOncology and @IEO. ASCO24 IDEA Awardee. Proud Kilifornian
ID: 325190920
27-06-2011 21:57:40
5,5K Tweet
2,2K Followers
958 Following
ER-low (ER =1-9%) behaves more or less as TNBC. The PROMENADE RWD french trial shows that the addition of neoadjuvant Pembrolizumab in ER-LOW improves pCR using the KN522 regime. #ESMO2024 #ESMO24 OncoAlert Paolo Tarantino Sara Tolaney ESMO - Eur. Oncology Erika Hamilton, MD
